|
|

Title: Protein-containing polymer composition for oral
administration
United States Patent: 6,004,583
Inventors: Plate ; Nikolai A. (Moscow, RU); Valuev; Lev I.
(Moscow, RU); Valueva; Tatyana A. (Moscow, RU); Staroseltseva; Ludmila K.
(Moscow, RU); Ametov; Alexander S. (Moscow, RU); Knyazhev; Vladimir A.
(Moscow, RU); Henis; Jay M.S. (St. Louis, MO)
Assignee: Orex Pharmaceutical Development Corp. (St.
Louis, MO)
Appl. No.: 691617
Filed: August 2, 1996
Abstract
A therapeutic-containing composition adapted for the oral
administration of a biologically active material which comprises a water
insoluble but water swellable polymer chemically modified with an enzyme
inhibitor containing a chemical functionality which has an interactive
affinity for target receptors located on the transport barrier walls of
the digestive tract of the intended recipient, and at least one
therapeutic of low oral bioavailability.
SUMMARY OF THE INVENTION
It is a general object of the invention to provide a
composition for oral administration of therapeutic and bioactive materials
whose oral availability is sufficiently limited under normal circumstances
that they cannot be effectively utilized with this route of
administration. More specifically, this invention deals with a composition
comprising a hydrophilic polymer chemically modified with an enzyme
inhibitor and a therapeutical material, often a protein or peptide, said
composition being adequate for oral administration.
A further object of the invention is to provide a therapeutic-containing
composition for oral administration which contains a water swellable
polymer modified with an enzyme inhibitor and a therapeutic material,
protein or peptide, said composition being in a tablet or capsule form,
typically such that it may safely pass through the gastric environment and
release the therapeutic ingredient in the small intestines.
A still further object of the invention is to increase the resistance of
protein or peptide therapeutics to the effects of various digestive
enzymes so as to enable such therapeutics to be more effectively
administered orally.
A further object of the invention is to increase the interaction of the
therapeutic-containing polymer hydrogels with selected transport barriers,
and interactive sites of the intestine and/or bowels to increase the
efficacy of the therapeutic substances.
A further object of the invention is to physically incorporate and entrap
within the chemically modified hydrogels a protein or a peptide or other
hard to deliver therapeutics without reacting, binding or substantially
modifying such therapeutics, to properly protect them from premature
decomposition, degradation, modification or destruction prior to its
delivery to the desired location in the body such as to the intestinal
barrier.
A further object of the invention is to deliver a therapeutically useful
amount of a therapeutic, bioactive, or biomimetic, protein or a peptide to
the target location in humans or animals to achieve useful therapeutic
effects at such dosing levels that may produce desirable results similar
to those when such therapeutic materials are injected into the body and/or
at levels significantly lower than would be required when the therapeutics
are given orally in the absence of the invention.
A further specific object of the invention is to provide an insulin
containing polymer composition which is chemically modified by an enzyme
inhibitor, such composition being contained within in a protective coating
or capsule such that the resulting tablet or capsule may be administered
orally to produce therapeutically useful effects equivalent or similar to
those produced when insulin is injected subcutaneously or intramuscularly,
and/or at levels much lower than would be required if insulin were to be
given orally in the absence of the invention.
Claim 1 of 69 Claims
1. A therapeutic-containing composition adapted for the
oral administration of a biologically active material comprising
(a) a water insoluble, but water swellable, polymer which contains at
least one enzyme inhibitor covalently bound to the polymer and a chemical
functionality which has an interactive affinity for target receptors
located on the transport barrier walls of the digestive tract of the
intended human or animal specie, wherein said chemical functionality is
either integral to the structure of said inhibitor or is covalently bound
to the polymer and
(b) one or more of therapeutic or biologically active agents.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|